Chongqing Lummy Pharmaceutical Co., Ltd. (SHE:300006)

Market Cap	5.37B +40.6%
Revenue (ttm)	771.02M -10.0%
Net Income	-107.30M
EPS	-0.10
Shares Out	1.06B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,461,729
Average Volume	40,670,906
Open	5.08
Previous Close	4.97
Day's Range	5.00 - 5.12
52-Week Range	2.77 - 6.14
Beta	0.32
RSI	48.87
Earnings Date	Mar 21, 2026

About SHE:300006

Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chongqing Lummy Pharmaceutical Co., Ltd. was founded in 1999 and is headquartered in Chongqing, China.

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1999
• Employees: 1,019
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300006

Financial Performance

In 2024, SHE:300006's revenue was 795.60 million, a decrease of -11.17% compared to the previous year's 895.59 million. Losses were -87.80 million, 883.5% more than in 2023.